DrugPatentWatch Database Preview
Drugs in Development Information for Azacytidine
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the development status for investigational drug Azacytidine?
Azacytidine is an investigational drug.
There have been 132 clinical trials for Azacytidine.
The most recent clinical trial was a Phase 3 trial, which was initiated on April 1st 2019.
The most common disease conditions in clinical trials are Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, and Preleukemia. The leading clinical trial sponsors are National Cancer Institute (NCI), M.D. Anderson Cancer Center, and Celgene Corporation.
Summary for Azacytidine
| US Patents | 0 |
| International Patents | 0 |
| US Patent Applications | 6,903 |
| WIPO Patent Applications | 0 |
| Japanese Patent Applications | 24 |
| Clinical Trial Progress | Phase 3 (2019-04-01) |
| Vendors | 91 |
Recent Clinical Trials for Azacytidine
| Title | Sponsor | Phase |
|---|---|---|
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | National Cancer Institute (NCI) | Phase 2 |
| Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting | M.D. Anderson Cancer Center | Phase 2 |
| Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase Chronic Myelogenous Leukemia | National Cancer Institute (NCI) | Phase 2 |
Clinical Trial Summary for Azacytidine
Top disease conditions for Azacytidine
Top clinical trial sponsors for Azacytidine
US Patents for Azacytidine
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
